Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2025-06-23 Board/Management Inform…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Galapagos benoemt Aaron Cox als Chief Financial Officer
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new Chief Financial Officer (Aaron Cox) and detailing his background and effective date. This type of announcement, concerning changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The document is short, formatted as a news release, and focuses entirely on personnel changes, not comprehensive financial results (ER/IR) or regulatory filings (10-K/AR). Therefore, the appropriate code is MANG.
2025-06-23 English
Galapagos Press Release_CFO_ENG.pdf
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new Chief Financial Officer (Aaron Cox) and detailing his background and effective date. This type of announcement, concerning changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The document is short, formatted as a news release, and focuses entirely on personnel changes, not comprehensive financial results (ER/IR) or regulatory filings (10-K/AR). Therefore, the appropriate code is MANG.
2025-06-23 English
Galapagos Press Release_CFO_NL.pdf
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new Chief Financial Officer (Aaron Cox) and detailing his background and responsibilities. This type of announcement, concerning changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The document is not a full financial report (10-K or IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). Therefore, the appropriate classification is MANG.
2025-06-23 Dutch
6-K Filing
Regulatory Filings
2025-06-20 English
Company announcement
Earnings Release Classification · 95% confidence The document is a press release from Galapagos NV, dated June 18, 2025, announcing new data from the ATALANTA-1 clinical trial for their drug candidate GLPG5101, presented at the ICML conference. It details efficacy (CR, MRD-negativity), safety, and manufacturing feasibility (vein-to-vein time). This format—a formal announcement summarizing key results, often including quotes from management and clinical investigators, and concluding with forward-looking statements and contact information—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/clinical updates. Since it focuses purely on clinical trial results and corporate progress rather than mandated financial statements (like 10-K or IR) or a transcript of a call, it fits best as an Earnings Release (ER), which often covers major operational/clinical milestones, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the structure and content (presenting new data/results), ER is the most appropriate fit among the specific options, as it functions as the initial public disclosure of these key performance indicators, even if not strictly quarterly financial earnings. Q4 2024
2025-06-19 Dutch
Company announcement
Earnings Release Classification · 97% confidence The document is a press release issued by Galapagos NV on June 18, 2025, announcing new clinical data for its drug candidate GLPG5101 presented at the ICML conference. It details efficacy (CR rate, MRD negativity) and safety profiles from the ATALANTA-1 Phase 1/2 study. This format—a formal announcement of scientific/clinical results outside of a scheduled earnings call or mandatory regulatory filing like a 10-K—is characteristic of an Earnings Release (ER) or a general press release detailing operational/clinical progress. Since it focuses on presenting key financial/clinical results (efficacy data, response rates) immediately following a presentation, it aligns best with the 'Earnings Release' definition, which covers the initial announcement of periodical financial/operational results (even if the 'period' here is a clinical trial update rather than a fiscal quarter). It is not a full Annual Report (10-K), a Call Transcript (CT), or a dedicated Investor Presentation (IP), but rather the initial public disclosure of these findings via a press release. Q4 2024
2025-06-19 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.